Kyowa Kirin
4151
Performance
About Kyowa Kirin
Kyowa Kirin is a Japan-based global specialty pharmaceutical company focused on developing antibody-based therapies and life-science innovations to treat cancer, kidney diseases, immune system disorders, and rare diseases. The group emphasizes research and development across bone and mineral diseases, hematologic malignancies, and hematopoietic stem cell gene therapy, with a global network spanning Asia-Pacific, North America, and Europe. Its mission centers on delivering life-changing value through diverse drug discovery technologies and partnerships while prioritizing patient care and global health outcomes.
Recent News
Amgen Ends Partnership with Kyowa Kirin on Immunology Drug, Despite Phase 3 Wins
CEO Moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression
Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for Global Biopharma and Healthcare Sectors
The Most Expensive Drugs on the Market in 2026 — and Why They Cost So Much
In the Clinic for March 10, 2026
Regulatory Actions for May 19, 2026
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Transcript
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Kyowa Kirin Secures FDA Approval for Crysvita Dosing Update
Cohere Acquires Pharma AI Startup Reliant AI to Expand Its Industry-Specific North Platform Amid Competition From OpenAI and Anthropic
Kyowa Kirin Abandons Touted Eczema Drug Following Safety Review
Amgen Gives up on Its Once-Prized Eczema Drug
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Recent Deals
No recent deals for this company.